Core Viewpoint - The article discusses the increasing regulatory scrutiny on the pharmaceutical e-commerce sector, particularly focusing on price transparency and fair competition, following the release of new guidelines by the State Administration for Market Regulation [3][4]. Regulatory Framework - The State Administration for Market Regulation issued the "Internet Platform Antitrust Compliance Guidelines," highlighting risks such as algorithm collusion, below-cost sales, and "choose one from two" practices [5][6]. - The guidelines emphasize four basic principles for platform operators: fairness in rules, ethical algorithms, compliance in competition, and targeted risk assessment based on industry characteristics [6]. Market Dynamics - The pharmaceutical e-commerce market is significant, with reported sales reaching 248.8 billion yuan in 2024, where third-party transaction service platforms account for 44% of the total [6]. - The dual role of platforms as both rule-makers and market participants complicates the competitive landscape, leading to price wars that affect both retail pharmacies and pharmaceutical companies [7]. Pricing Issues - The article highlights instances where online prices for medications are significantly lower than offline prices, raising concerns about the sustainability of such pricing strategies [7][8]. - The guidelines prohibit practices that lead to below-cost sales and require transparency in pricing, particularly in the context of promotional activities [8][9]. Compliance and Risk Assessment - Compliance with the new regulations will require platforms to assess the appropriateness of subsidies, the voluntary nature of merchant participation, and the duration of promotional activities [8][9]. - The article notes that excessive subsidies leading to below-cost pricing could be deemed anti-competitive, especially if they aim to eliminate smaller competitors [9]. Transparency and Fair Competition - The regulatory focus aims to ensure that both online and offline pricing is fair and transparent, with a goal of promoting healthy competition in the pharmaceutical market [12][13]. - Platforms are advised to avoid practices that could restrict competition, such as exclusive arrangements that limit the market space for other operators [12][13].

Core Viewpoint - The recent regulatory measures aim to strengthen oversight of the pharmaceutical market, particularly focusing on price transparency and fair competition among online platforms and medical institutions [1][7]. Group 1: Regulatory Framework - The State Administration for Market Regulation has issued the "Internet Platform Antitrust Compliance Guidelines," which outlines new risks such as algorithm collusion and selling below cost [2][3]. - The guidelines emphasize four fundamental principles: fairness in rules, ethical algorithms, compliance in competition, and targeted risk assessment based on industry characteristics [3]. - The "Medical Institution Price Disclosure Regulations" has been revised for the first time in 24 years, now including online hospitals and requiring detailed price disclosures for online prescriptions [1][7]. Group 2: Market Dynamics - The pharmaceutical e-commerce sector is projected to reach a sales total of 248.8 billion yuan in 2024, with third-party transaction service platforms accounting for 44% of this figure [3]. - Online platforms are seen as both rule-makers and market participants, leading to potential price wars that could impact traditional pharmacies and disrupt existing pricing management systems [4][5]. - A notable case highlighted the disparity in drug prices, where online prices were significantly lower than those in physical stores, raising concerns about market fairness [4]. Group 3: Compliance and Risks - The guidelines prohibit practices such as using promotional activities to establish vertical monopoly agreements and selling below cost without justification [5][6]. - The assessment of compliance risks will focus on the appropriateness of subsidy levels, the voluntary nature of merchant participation, and the duration of promotional activities [5][6]. - Concerns have been raised regarding the safety risks associated with promotional behaviors in the pharmaceutical sector, particularly in relation to prescription drugs [6]. Group 4: Transparency and Competition - The National Healthcare Security Administration has initiated actions to compare online drug prices with various channels to ensure fairness and prevent excessive pricing [7]. - Both regulatory approaches aim to clarify the true bottom line of drug and medical service prices, promoting healthy competition in the pharmaceutical market [8]. - Platforms must avoid practices that could lead to monopolistic behavior, such as exclusive arrangements that limit the survival of other operators [8][9].